La rejilla horizontal antipulgar según técnica de Mollin modificada

El presente trabajo presenta un aparato auxiliar fijo para evitar el hábito de succión digital, descrito por el Dr. Mollin (USA) y modificado por el Dr. J. M. Salagnac (Francia). Consiste en una rejilla de disposición horizontal que además de eliminar el hábito de succión, ayuda en la corrección de las alteraciones dentarias ya establecidas y se compara con otros sistemas mecánicos utilizados habitualmente

Effect of water contamination on the shear bond strength of five orthodontic adhesives

Objectives: To evaluate the shear bond strength and site of failure of brackets bonded to dry and wet enamel. Study design: 50 teeth were divided into ten groups of 5 teeth each (10 surfaces). In half the groups enamel was kept dry before bonding, and in the other half distilled water was applied to wet the surface after etching. The following groups were established: 1)Acid/Transbond-XT (dry/wet) XT; 2) Transbond Plus Self Etching Primer (TSEP)/Transbond-XT paste (dry/wet); 3) Concise (dry), Transbond MIP/Concise (wet), 4) FujiOrtho-LC (dry/wet); 5) SmartBond (dry/wet). Brackets were bonded to both buccal and lingual surfaces. Specimens were stored in distilled water (24 hours at 37ºC) and thermocycled. Brackets were debonded using a Universal testing machine (cross-head speed 1 mm/min). Failure sites were classified using a stereomicroscope. Results: No significant differences in bond strength were detected between the adhesives under wet and dry conditions except for Smart- Bond, whose bond strength was significantly lower under dry conditions. For all the adhesives most bond failures were of mixed site location except for Smartbond, which failed at the adhesive-bracket interface. Conclusions: Under wet conditions the bonding capacity of the adhesives tested was similar than under dry conditions, with the exception of SmartBond which improved under wet condition

Sistemas insulares energéticamente sostenibles: Estudio de aplicación de la tecnología power to gas en la isla de Gran Canaria

El actual sistema de generación eléctrica de la isla de Gran Canaria se caracteriza por ser un sistema pequeño, poco eficiente, aislado y por estar constituido principalmente por tecnología sustentada en combustibles fósiles. Ello conlleva un elevado coste de generación eléctrica, así como de emisiones. Con la finalidad de conseguir un sistema eléctrico más favorable técnica, económica y medioambientalmente se dimensiona un sistema de generación 100% renovable. Se proponen cuatro posibles modelos. Se selecciona un modelo basado en generación eólica y fotovoltaica, el cual implementa un sistema Power to Gas que permite adaptar la generación a la demanda requerida por el sistema, además de considerar limitar la potencia del sistema Power to Gas. Finalmente, la alternativa proyectada resulta ser una opción más rentable y sostenible que el sistema de generación actual

Estudio tecno-económico sobre la ampliación de la capacidad de recarga de la hidrogenera de Fundación Hidrógeno de Aragón

La estación de recarga de vehículos de hidrógeno de la Fundación Hidrógeno Aragón se caracteriza por disponer de una capacidad de recarga de 350 bar. Dicha capacidad de recarga se encuentra obsoleta frente a la capacidad de recarga de los vehículos actuales, definida a 700 bar. Con la finalidad de adaptarse al nuevo estándar, se dimensiona una estación de recarga de vehículos de hidrógeno con capacidad de recarga a 700 bar basada en la instalación existente. Para ello se proponen cinco posibles configuraciones. En base a los requerimientos establecidos y al análisis tecno-económico de las cinco configuraciones propuestas se selecciona la configuración óptima para su implantación. Finalmente, la configuración seleccionada resulta ser la opción que permite un mayor número de recargas consecutivas y que presenta el menor tiempo de recarga al tratarse de una recarga en cascada. Además, la configuración seleccionada, integra los equipos de la instalación actual y presenta un alto grado de adaptabilidad ante futuras ampliaciones de la instalación.<br /

Bond strength of orthodontic brackets using different light and self-curing cements

The purpose of the study was to evaluate the shear bond strength of stainless steel orthodontic brackets directly bonded to extracted human premolar teeth. Fifty teeth were randomly divided into five groups: (1) System One (chemically cured composite resin), (2) Light Bond (light-cured composite resin), (3) Vivaglass Cem (self-curing glass ionomer cement), (4) Fuji Ortho LC (light-cured glass ionomer cement) used after 37% orthophosphoric acid–etching of enamel (5) Fuji Ortho LC without orthophosphoric acid–etching. The brackets were placed on the buccal and lingual surfaces of each tooth, and the specimens were stored in distilled water (24 hours) at 37°C and thermocycled. Teeth were mounted on acrylic block frames, and brackets were debonded using an Instron machine. Shear bond strength values at fracture (Nw) were recorded. ANOVA and Student-Newman-Keuls multiple comparison tests were performed (P < .05). Bonding failure site was recorded by stereomicroscope and analyzed by Chi-square test, selected specimens of each group were observed by scanning electron microscope. System One attained the highest bond strength. Light Bond and Fuji Ortho LC, when using an acid-etching technique, obtained bond strengths that were within the range of estimated bond strength values for successful clinical bonding. Fuji Ortho LC and Vivaglass Cem left an almost clean enamel surface after debracketing.This research project was supported, in part, by grant CICYT/FEDER MAT2001-2843-C02. RED CYTED VIII.J

Étude du marché du travail des diplômés de Médicine Familière à Tabasco, Mexique

The study of the labor market and the perception of the postgraduate studies of graduates from the specialty of family medicine of the Mexican Social Security Institute (IMSS) in Tabasco, allowed a cross-sectional descriptive investigation. From the universe of 201 graduates of the Specialty of Family Medicine, a survey sample of 103 graduates (51%) was determined.Among the results obtained, 59% of the graduates were between 30 and 39 years of age. The group of women predominated with 57%, compared to the group of men with 43%. The majority of the graduated doctors were married (57%), and the Juárez Autonomous University of Tabasco (UJAT) was found as the main university institution, with 66% provenance. 90% worked with clinical care functions in their current job and 96% were very satisfied with the training received. 48% consider that the knowledge acquired has served them to a high degree for professional performance, with the profile of graduates mostly married women between 30 and 39 years of age, coming from the UJAT degree in Surgery, labor-related to the health sector in clinical-care operative activities and currently satisfied with the work they carry out and with the academic training they received.El estudio del mercado laboral y la percepción sobre los estudios de posgrado de los egresados de la especialidad de medicina familiar del Instituto Mexicano del Seguro Social (IMSS) en Tabasco permitió una investigación de tipo descriptivo, transversal. El universo fueron 201 egresados de la Especialidad de Medicina Familiar, Se determinó una muestra a encuestar de 103egresados (51%).Dentro de los resultados obtenidos el 59% de los egresados tuvieron entre 30 y 39 años de edad. El grupo de las mujeres predominó con un 57%, en relación al grupo de los hombres que fue de 43 %. La mayoría de los médicos egresados estaban casados 57%, y se encontró a la Universidad Juárez Autónoma de Tabasco (UJAT) como principal institución universitaria de procedencia 66%. El 90% se desempeñaron con funciones clínica asistenciales en su empleo actual y el 96% estuvieron muy satisfechos con la formación recibida. El 48% considera que los conocimientos adquiridos le han servido en un alto grado para el desempeño profesional, siendo el perfil de los egresados en su mayoría mujerescasadas entre 30 y 39 años, procedentes de la licenciatura de médico cirujanode la UJAT, laboralmente vinculadas al sector salud en actividades operativasclínico-asistenciales y actualmente satisfechas con el trabajo que realizan y con la formación académica recibida.L’étude du marché du travail et la perception des études du troisième cycle des diplômés de la spécialité de Médecine Familiale de l’Institut Mexicain de SécuritéSociale (IMSS) à Tabasco, ont permis de mener une recherche descriptive transversale. L’univers était composé de 201 diplômés de la spécialité de Médicine Familiale et un échantillon de 103 diplômés à enquêter a été déterminé (51%). Parmi les résultats obtenus, 59% des diplômés avaient entre 30 et 39 ans. Le groupe des femmes a prédominé avec 57% par rapport au groupe des hommes qui a été 43%. La plupart des médecins diplômés étaient mariés, 57% et l’Université Juárez Autonome de Tabasco (UJAT) a été identifiée comme la principale institution universitaire d’origine, 66%. 90% ont travaillé avec des fonctions de soins cliniques et 96% ont manifesté se sentir satisfaits avec la formation reçue. 48% considère que les connaissances développés les ont aidés en termes de performance professionnelle, le profil des diplômés étant majoritairement des femmes mariées entre 30 et 39 ans, issues du diplôme de chirurgien de l’UJAT et, travaillant dans le secteur de la santé dans des activités opérationnelles de soins cliniques, se disant satisfaites du travail réalisé tout comme de la formation reçue

Sirt1 Activation With Neuroheal Is Neuroprotective But Sirt2 Inhibition With Ak7 Is Detrimental For Disconnected Motoneurons

Sirtuin 1 (SIRT1) activity is neuroprotective, and we have recently demonstrated its role in the retrograde degenerative process in motoneurons (MNs) in the spinal cord of rats after peripheral nerve root avulsion (RA) injury SIRT2 has been suggested to exert effects opposite those of SIRT1, however, its roles in neurodegeneration and neuron response after nerve injury remain unclear Here we compared the neuroprotective potentials of SIRT1 activation and SIRT2 inhibition in a mouse model of hypoglossal nerve axotomy This injury induced a reduction of around half MN population within the hypoglossal nucleus by a non apoptotic neurodegenerative process triggered by endoplasmic reticulum (ER) stress that resulted in activation of the unfolded protein response mediated by IREI alpha and XBP1 by 21 days post injury Both SIRT1 activation with NeuroHeal and SIRT2 inhibition with AK7 protected NSC-34 motor neuron like cells against ER stress in vitro. In agreement with the in vitro results, NeuroHeal treatment or SIRT1 overexpression was neuroprotective of axotomized hypoglossal MNs in a transgenic mouse model In contrast, AK7 treatment or SIRT2 genetic depletion in mice inhibited damaged. MN survival To resolve the in vitro/in vivo discrepancies, we used an organotypic spinal cord culture system that preserves glial cells In this system, AK7 treatment of ER stressed organotypic cultures was detrimental for MNs and increased microglial nuclear factor-kB and the consequent transcription of cytotoxic pro inflammatory factors similarly The results highlight the importance of glial cells in determining the neuroprotective impact of any treatment

A phylogenetic study of covid-19 data from Aragon and Catalonia over a year: learning Bioinformatics during a world pandemic

We present here a one year variability analysis of SARS-CoV-2 virus in the Aragon area, comparing it to neighboring Catalonia and focusing on the UK-variant. Research was performed within a Bioinformatics course. Both a detailed assessment on the value of this methodology and novel research conclusions were extracted.Presentamos aquí un análisis de variabilidad durante un año del virus SARS-CoV-2 en el área de Aragón, comparándolo con la vecina Cataluña y centrándonos en la variante del Reino Unido. La investigación se realizó dentro de un curso de Bioinformática. Se extrajeron tanto una evaluación detallada sobre el valor de esta metodología como conclusiones novedosas de la investigación

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Simple Summary Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. In this multicentric retrospective series of ovarian cancer patients, we evaluated chemotherapy results upon progression to maintenance with PARPi in the relapsed setting. We further selected the population of platinum-sensitive patients (according to the classical definition) retreated with platinum (n = 74). In this platinum-sensitive population, overall response rate and survival outcomes of platinum rechallenge after PARPi were similar to historical series of the prePARPi era. However, within this group, analysis according to BRCA status showed that BRCA mutant patients (n = 35) presented higher rates of progression and worse survival outcomes under subsequent platinum than BRCA wild type patients (n = 39), with statistically significant differences. This is the largest real-world data series of ovarian cancer patients treated with platinum rechallenge in the post-PARPi scenario. Background: Despite impressive progression-free survival (PFS) results from PARP inhibitors (PARPi) in ovarian cancer, concerns about their effect on post-progression treatment outcomes have recently arisen, particularly when administered in the relapsed setting. Overlapping mechanisms of resistance between PARPi and platinum have been described, and optimal therapies upon progression to PARPi are unknown. We communicate real-world data (RWD) on outcomes of subsequent chemotherapy upon progression to PARPi used as maintenance in ovarian cancer relapses, particularly focusing on platinum rechallenge, according to BRCA status. Methods: Data from high-grade serous or endometrioid ovarian cancer patients who received subsequent chemotherapy after progression to maintenance PARPi in the relapsed setting, in 16 Catalan hospitals between August 2016 and April 2021, and who were followed-up until July 2021, were included. Endpoints were overall response rate (ORR), and PFS and overall survival (OS) measured from the subsequent chemotherapy starting date. Results: 111 patients were included [46 (41.4%) presented pathological BRCA1/2 mutations, 8 (7.5%) in other homologous recombination-related genes]. Sixty-four patients (57.7%) had received two prior chemotherapy lines, including the one immediately prior to PARPi. PARPi were niraparib (n = 60, 54.1%), olaparib (n = 49, 44.1%), and rucaparib (n = 2, 1.8%). A total of 81 patients remained platinum-sensitive (PS population) after progression to PARPi (when progression-free interval [PFI] was >6 months after the last cycle of prior platinum) [median PFI 12.0 months (interquartile range, IQR, 8.8-17.1)]. Of those, 74 were treated with subsequent platinum regimens, with the following results: ORR of 41.9%, median PFS (mPFS) of 6.6 months (95% CI 6-9.2), and median OS (mOS) of 20.6 months (95% CI 13.6-28.9). Analysis of these 74 patients according to BRCA status showed that PFIs for BRCA mutant and non BRCA-mutant patients were 13.6 [IQR11.2-22.2] and 10.3 [IQR 7.4-14.9] months, respectively (p = 0.010); ORR were 40.0% versus 43.6%, respectively; Rates of progression (as best response) to subsequent platinum were 45.7% versus 17.9%, respectively (p = 0.004); mPFS and mOS were 3.5 (95% CI 2.5-8.6) versus 7.5 months (95% CI 6.5-10.1, p = 0.03), and 16.4 (95% CI 9.3-27.5) versus 24.2 months (95% CI 17.2-NR, p = 0.036), respectively. Conclusion: This is the largest series of real-world data on ovarian cancer patients retreated with platinum in the post-PARPi scenario, separately analyzing BRCA mutant and non-mutant patients, to our knowledge. In our platinum-sensitive population, rechallenge with platinum after progression upon PARPi in the 3rd or later lines for ovarian cancer relapses shows relevant ORR and similar PFS outcomes to historical series of the prePARPi era. However, BRCA mutant patients presented significantly higher rates of progression under subsequent platinum and worse survival outcomes associated with subsequent platinum than non-BRCA-mutant patients

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

Background: Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy combination shows limited efficacy and recurrences often occur in less than 12 months. ABTL0812 is a novel drug that selectively kill cancer cells by cytotoxic autophagy and has shown anticancer efficacy in preclinical models of EC in combination with CP. Methods: ENDOLUNG was an open-label, phase 1/2 clinical trial designed to determine the safety and efficacy of Ibrilatazar (ABTL0812) with CP in patients with advanced/recurrent EC and non-irradiable stage III and IV squamous non-small cell lung cancer (sq-NSCLC). The phase 1 part consisted of a 3 + 3 de-escalation design followed by an expansion cohort with 12 patients. The primary endpoint was safety. ABTL0812 starting dose was 1300 mg tid combined with carboplatin at area under the curve (AUC) 5 and paclitaxel at 175 mg/m2 both administered every 21 days for up to 8 cycles. The phase 2 part included a total of 51 patients. The primary endpoint was overall response rate (ORR) and the secondary endpoints included duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: During the phase 1 only one dose limiting toxicity (DLT), a grade 4 neutropenia, was observed in 1 out of 6 patients, thus no de-escalation was applied. One additional DLT, a grade 3 febrile neutropenia, was observed in the expansion cohort, thus the recommended phase 2 dose (RP2D) for ABTL0812 was established at 1300 mg tid. Most frequent hematological adverse events (AE) of the combination were neutropenia (52.9%), anemia (37.3%) and thrombocytopenia (19.6%). Nausea (66.7%), asthenia (66.7%), diarrhea (54.9%) and vomiting (54.9%) were the most frequent non-hematological adverse events (AEs). The combination of ABTL0812 plus CP showed an ORR of 65.8% (13.2% complete response and 52.6% partial response) with a median DOR of 7.4 months (95% CI: 6.3-10.8 months). Median PFS was 9.8 months (95% CI: 6.6-10.6) and median OS 23.6 months (95% CI 6.4-ND). Pharmacokinetic parameters were compatible with target engagement observed in preclinical studies, and blood pharmacodynamic biomarkers indicated sustained target regulation during, at least, 28 days after starting the treatment. Conclusions: This study suggests that the combination of ABTL0812 with CP is safe and feasible with an encouraging activity in patients with advanced/recurrent EC. Our data warrant further confirmation in prospective randomized trials